ERBB2 and neoplasm: Pyrotinib binds covalently to the ATP-binding sites of the kinase domains of intracellular epidermal growth factor receptor and HER-2, preventing formation of intracellular homo- and heterodimerization of epidermal growth factor receptor and HER-2 in tumor cells, thereby inhibiting its autophosphorylation.